Stanford Cancer Institute
Showing 11-20 of 28 Results
-
Roger Warnke
Ronald F. Dorfman, M.B.B.ch., FRCPath, Professor in Hematopathology, Emeritus
Current Research and Scholarly InterestsAs an Emeritus Professor, I no longer have a research laboratory and am now fully retired.
-
Robert Waymouth
Robert Eckles Swain Professor of Chemistry and Professor, by courtesy, of Chemical Engineering
BioRobert Eckles Swain Professor in Chemistry Robert Waymouth investigates new catalytic strategies to create useful new molecules, including bioactive polymers, synthetic fuels, and sustainable plastics. In one such breakthrough, Professor Waymouth and Professor Wender developed a new class of gene delivery agents.
Born in 1960 in Warner Robins, Georgia, Robert Waymouth studied chemistry and mathematics at Washington and Lee University in Lexington, Virginia (B.S. and B.A., respectively, both summa cum laude, 1982). He developed an interest in synthetic and mechanistic organometallic chemistry during his doctoral studies in chemistry at the California Institute of Technology under Professor R.H. Grubbs (Ph.D., 1987). His postdoctoral research with Professor Piero Pino at the Institut fur Polymere, ETH Zurich, Switzerland, focused on catalytic hydrogenation with chiral metallocene catalysts. He joined the Stanford University faculty as assistant professor in 1988, becoming full professor in 1997 and in 2000 the Robert Eckles Swain Professor of Chemistry.
Today, the Waymouth Group applies mechanistic principles to develop new concepts in catalysis, with particular focus on the development of organometallic and organic catalysts for the synthesis of complex macromolecular architectures. In organometallic catalysis, the group devised a highly selective alcohol oxidation catalyst that selectively oxidizes unprotected polyols and carbohydrates to alpha-hyroxyketones. In collaboration with Dr. James Hedrick of IBM, we have developed a platform of highly active organic catalysts and continuous flow reactors that provide access to polymer architectures that are difficult to access by conventional approaches.
The Waymouth group has devised selective organocatalytic strategies for the synthesis of functional degradable polymers and oligomers that function as "molecular transporters" to deliver genes, drugs and probes into cells and live animals. These advances led to the joint discovery with the Wender group of a general, safe, and remarkably effective concept for RNA delivery based on a new class of synthetic cationic materials, Charge-Altering Releasable Transporters (CARTs). This technology has been shown to be effective for mRNA based cancer vaccines. -
Irving Weissman
Virginia & D.K. Ludwig Professor of Clinical Investigation in Cancer Research, Professor of Pathology, and of Developmental Biology
Current Research and Scholarly InterestsStem cell and cancer stem cell biology; development of T and B lymphocytes; cell-surface receptors for oncornaviruses in leukemia. Hematopoietic stem cells; Lymphocyte homing, lymphoma invasiveness and metastasis; order of events from hematopoietic stem cells [HSC] to AML leukemia stem cells and blood diseases, and parallels in other tissues; discovery of tumor and pathogenic cell 'don't eat me' and 'eat me' signals, and translation into therapeutics.
-
Paul Wender
Francis W. Bergstrom Professor and Professor, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsMolecular imaging, therapeutics, drug delivery, drug mode of action, synthesis
-
Wen-Kai Weng, MD, PhD
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and, by courtesy, of Dermatology
Current Research and Scholarly InterestsMy research interest is on immunotherapy (including allogeneic transplant) of cancer. I have studies the mechanism of monoclonal antibody therapy in lymphoma patients and am currently working on designing new strategy to enhance the clinical efficacy of antibody therapy by infusing expanded NK cells. I am also interested in using tumor vaccine along with hematopoietic cell transplant.
-
Marius Wernig
Professor of Pathology and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsEpigenetic Reprogramming, Direct conversion of fibroblasts into neurons, Pluripotent Stem Cells, Neural Differentiation: implications in development and regenerative medicine
-
Robert West
Sabine Kohler, MD, Professor of Pathology
Current Research and Scholarly InterestsRob West, MD, PhD, is a Professor of Pathology at Stanford University Medical Center. He is a clinician scientist with experience in translational genomics research to identify new prognostic and therapeutic markers in cancer. His research focus is on the progression of neoplasia to carcinoma. His lab has developed spatially oriented in situ methods to study archival specimens. He also serves as a surgical pathologist specializing in breast pathology.
-
Lynn Marie Westphal, M.D.
Professor of Obstetrics and Gynecology (Reproductive Endocrinology and Infertility) at Stanford University Medical Center, Emerita
Current Research and Scholarly InterestsInfertility, fertility preservation, oocyte cryopreservation
